Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03696680 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal

Study acronym: STEREO-HBM
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 4v8
  2. Primary completion date: Jun 2024 to Jun 2027
    • Study completion date: Jan 2025 to Jan 2028
    • Eligibility criteria shortened, about 7 words
    v7
  3. Study sites: 2 to 3v6
  4. Primary completion date: Jun 2022 to Jun 2024
    • Study completion date: Jan 2023 to Jan 2025
    • Eligibility criteria expanded, about 32 words
    v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 3 to 2v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary completion date: Mar 2022 to Jun 2022
    • Study completion date: Dec 2022 to Jan 2023
    • Start date changed from estimate of Oct 2018 to Jan 16, 2019
    • Site details revised at 3 of 3 sites
    • Eligibility criteria expanded, about 1 word
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
Trial Details
NCT Number NCT03696680
Lead Sponsor Centre Francois Baclesse
Collaborators: ANOCEF/IGCNO, Groupement Interrégional de Recherche Clinique et d'Innovation
Conditions
(from sponsor)		 Hemorrhagic Brain Metastases
Related terms Brain Neoplasms
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov